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Abstract 
Background: Chronic infections with Pseudomonas aeruginosa are a leading cause 
of morbidity in patients with cystic fibrosis (CF). Tobramycin nebulizer solution 
(TNS) is indicated for maintenance therapy in CF patients. TOBI
®
 is a tobramycin 
nebulizer solution (TNS) approved by FDA for maintenance therapy for patient with 
CF. Adherence to recommended therapy in CF has always been a challenge and new 
generation nebulizers are increasingly used “off label” to reduce the time required for 
inhalation, potentially improving patient compliance. 
Objectives: to assess the performance of selected recent nebulizer delivery systems 
for determination the optimum combinations to deliver TOBI
®
. Using the relative 
lung bioavailability of TOBI
®
 to the lungs in healthy volunteers, following inhalation 
from selected nebulizer delivery systems, using a urinary pharmacokinetics method. 
In vitro aerodynamic characteristics of the nebulized dose were also determined.  
Methods: Serial urine samples were collected from 12 healthy volunteers up to 24 hrs 
post-inhalation of TOBI
®
 inhaled solution following delivery by Pari LC Plus
®
, 
Sidestream
®
, NE-U22-E Omron
®
 and Aeroneb
® 
Go nebulizers. In vitro aerodynamic 
characteristics of the nebulized dose were also determined according to the CEN 
(Committee European de Normalization) method.   
Results: The mean (SD) relative lung bioavailability from Pari LC Plus
®
, 
Sidestream
®
, Omron
®
, and Aeroneb
®
 Go nebulizers was 4.9 (0.5), 3.9 (0.5), 7.1  (1.3), 
and 7.7  (0.7) %, respectively. The mean (SD) mass median aerodynamic diameter 
(MMAD) of the drug particles from the same systems was 2 (0.2), 2 (0.2), 1.2 (0.03) 
and 2.0 (0.1) µm, and the corresponding fine particle doses (FPD) were 2.2 (0.23), 1.5 
(0.2), 3.44 (0.3) and 2.8 (0.3) mg. 
Conclusion: The data obtained from in-vitro and in-vivo studies reflect poor relative 
lung bioavailability of tobramycin following jet nebulization.  
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Introduction 
Cystic fibrosis (CF) is an autosomal recessive disease that affects approximately 
60,000 people worldwide [1]. Chronic pulmonary Pseudomonas aeroginosa infection 
is the most common cause of morbidity and mortality in patients with CF and 
bronchiectasis [2]. 
Aminoglycosides are the antibiotics most effective against P. aeruginosa infections 
[3]. Parenteral administration of aminoglycoside antibiotics is limited by poor 
penetration into bronchial secretions and impairment of their biological activity by 
purulent secretions, resulting in peak sputum concentrations equivalent to only 12-
20% of serum concentrations [4]. However, because components of CF sputum bind 
aminoglycosides, sputum concentrations must exceed 10 to 25 fold above the 
minimum inhibitory concentration (MIC), to overcome the effect of sputum binding 
on aminoglycoside availability to bacterial targets.  Thus, to attain efficacious drug 
concentrations at the site of infection, large parenteral doses of aminoglycoside must 
be administered, placing the patient at risk to aminoglycoside-associated ototoxicity 
and nephrotoxicity [5]. 
Delivery of aminoglycosides by the aerosolised route to the lower respiratory tract is 
an attractive alternative method of antibiotic delivery that allows direct application of 
high concentrations of antibiotic to the site of the infection, with minimal systemic 
absorption and associated toxicity [6]. Aerozolised tobramycin is often prescribed as 
part of the treatment regimen for pulmonary P. aeruginosa infection in CF patients. 
There are many advantages for its use that make it the antibiotic of choice in the 
treatment of pulmonary infections in CF. It is more effective than other antibiotics 
against P. aeruginosa strains that are found in the sputum of pulmonary CF and 
bronchiectasis patients [7-12]. It is also well-tolerated and the least toxic drug of the 
aminoglycosides [13]. TOBI® (tobramycin nebulized solution 300mg/5ml) is 
licensed as maintenance therapy for chronic pulmonary P. aeruginosa infections in 
CF patients. The manufacturer of TOBI® recommends nebulization of the solution 
with the Pari LC Plus® jet nebuliser in combination with the DeVilbiss Pulmo-Aide® 
compressor. However, poor lung deposition and high drug wastage, due to a high 
residual volume, are the main disadvantages of this combination. Therefore, new 
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nebuliser systems have been investigated to improve tobramycin aerosol delivery to 
the peripheral airways and minimize residual drug wastage. Many in-vitro and in-vivo 
studies have been investigated to achieve these purposes [ 14-27] 
In-vivo studies the pharmacokinetic (PK) methods can provide accurate and 
reproducible quantification of drug delivery by measuring plasma levels to reflect 
lung deposition and bioavailability [28,29]. PK technique has been difficult to apply 
to most inhaled drugs, as the doses delivered are generally too small (microgram 
quantities), and the resulting plasma levels are low, which may be below the accurate 
detection limits of standard assays.  Recently, more sensitive assay methods have 
been developed to overcome this problem. The other problem of plasma PK technique 
is the drug plasma level involves pulmonary absorption resulting from lung 
deposition, and gastro-intestinal absorption of the swallowed fraction resulting from 
oropharyngeal deposition. Where gastro-intestinal absorption is excluded, systemic 
levels will reflect total lung deposition. This is achieved by blocking all 
gastrointestinal absorption with oral charcoal co-administration, or used sampling 
during the lag time of the absorption phase.  
Borgström et al. [30] used charcoal-block technique to quantify the percentage of 
inhaled dose deposited in the lungs, and to determine absolute pulmonary 
bioavailability for formoterol, ipratropium bromide, budesonide, salbutamol, and 
terbutaline sulphate.   
Many studies have used PK technique to compare different inhaler devices, such as 
for dry powder, pressurised aerosol and nebulized formulations, and to evaluate the 
bioequivalence of different drug formulations. Newnham et al. [31] have determined 
salbutamol plasma concentrations (Cmax) to compare standard MDIs and modified 
actuator devices. Newnham & Lipworth [32] used the same methodology to compare 
performance of two nebulizer delivery systems, Ventstream
®
 and Hudson Updraft II
®
.   
Inhaled doses usually are small, and only 10% of dose deposits into the lungs [33], so 
plasma concentration of drug is generally very low, especially if the volume 
distribution is large, and concentration is therefore difficult to measure.   
The serum (tmax) may vary for different drugs due to differences in the rate of 
absorption across to lung epithelium, or to prolonged binding to lung receptors [34] or 
airway mucus [35], so the measurement of urinary excretion has been developed as an 
alternative indirect method for evaluating pharmacokinetics of inhaled drugs. A 
urinary PK method is ideal for polar and basic drugs such as β-agonists and 
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aminoglycosides, which have a high renal clearance rate and are highly excreted in 
urine. Thus the concentration of the drug in urine is often high in comparison to that 
of plasma, because of the comparatively small urine volume. Therefore, in these 
cases, urine provides useful PK data following inhalation [36,37]. It has been 
successfully employed in the determination of the relative lung bioavailability of 
many inhaled drugs, such as salbutamol [38], sodium cromoglycate [39],  nedocromil 
sodium [40],  inhaled gentamicin [41, 42]  and inhaled tobramycin [43].  
In a comparative study of plasma and urinary PK methods, Clark et al. [44] reported 
no significant differences apparent between salbutamol urinary excretion and 
salbutamol plasma level.   
Another indirect urinary PK method has been introduced. This method is based on the 
measurement of urinary excretion in the first 30 min after inhalation to differentiate 
between the components of lungs and gastrointestinal absorption of inhaled drug. 
Hindle & Chrystyn [45] used the advantage of the biphasic renal excretion (over 24 
hours) to determine and compare the relative bioavailability of salbutamol post-oral 
and inhaled dose. The initial elimination (i.e. 30 min) represents the fraction of dose 
administrated to the lungs, rapidly absorbed via the alveoli, then excreted unchanged 
by the kidneys. The second phase represents the dose swallowed after impaction in the 
oropharynx. They showed that little drug is excreted in urine 30 min after oral 
ingestion because of the lag time between administration and start of absorption. The 
urine drug recovery 30 minutes after inhalation was significantly greater.   
Hindle et al. [46] have measured the relative bioavailability to the lungs using 30-
minute urine recovery of salbutamol following a variety of inhalation techniques in 10 
healthy volunteers. They observed significantly greater elimination in the first 30 min 
when drug was inhaled slowly (10 L/min) versus quickly (50 L/min), and with breath-
holding (10s) versus without breath-holding. 
Recently, the 30-min urinary salbutamol method has been validated, and showed a 
linear and reproducible relationship with inhaled dose [47]. Tomlinson et al. [48] have 
assessed different methods of inhalation from salbutamol MDIs by the 30-min urinary 
excretion method. 
The 30-min urinary salbutamol method could not distinguish between the three 
products. Total systemic delivery can be assessed by using urinary excretion, 
especially if the molecules are polar or basic [49].   
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Borgström et al. [50] compared gamma scintigraphy and PK methods for 
determination of pulmonary deposition of inhaled terbutaline. The mean (S.D) total 
terbutaline lung deposition identified by gamma scintigraphy was 26.9 (3.8) % of 
nominal dose, whilst 21.1 (3.2) % was collected by urinary excretion post-terbutaline 
inhalation with charcoal co-administration. In another study, Derendorf et al. [51] 
obtained similar data from PK and gamma scintigraphy methods in comparing 
between oral (with charcoal co-administration) and inhaled glucocorticoid.  
Gamma scintigraphy identified total lung deposition of a drug that is cleared from the 
lungs either by absorption into the systemic circulation or by mucociliary clearance, 
whereas the PK methods identify total lung deposition (not regional), and cannot 
differentiate between deposition into different zones of the lungs or the amount 
removed by mucociliary clearance [52]. 
In this study, we have investigated the urinary pharmacokinetics of tobramycin post-
nebulisation, and the sampling periods have been designed to establish whether tmax is 
prolonged. In addition, we have determined the aerodynamic characteristics of the 
emitted dose to determine if these could influence lung deposition. 
Methods 
Ethical approval was obtained from the University of Bradford, and all volunteers 
gave signed informed consent. All subjects were healthy adult and non-smoking 
volunteers. The demographic details of volunteers who completed the study are 
shown in Table 1.  
Table 1  Volunteer demographics. 
No. Volunteer Gender Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
1 A Male 36 175 80 
2 B Male 33 175 73 
3 C Male 43 180 85 
4 D Male 27 173 72 
5 E Male 32 170 80 
6 G Female 24 172 62 
7 H Male 34 180 74 
8 J Male 25 168 68 
9 K Male 40 170 84 
10 L Female 26 175 85 
11 N Male 39 170 90 
12 W Female 31 175 60.33 
 Mean - 32.5 173.583 76.110 
 SD - 6.230 3.848 9.479 
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Different nebulizer delivery systems were used to assess their ability to deliver 
inhaled tobramycin to lungs: two different designs of jet nebulizers and two new 
nebulizers based on mesh technology. The jet nebulizers were the breath-enhanced 
Pari LC Plus
®
 attached to PariBoyN
®
 compressor (Pari GmbH; Starnberg, Germany), 
and the constant output Sidestream
®
   (Medic-Aid Ltd; West Sussex, UK) attached to 
Porta-Neb
®
 compressor (Profiles, UK). The new nebulizers were NE-U22-E Omron
®
 
(Omron, Japan) static mesh nebulizer (moderate frequency) and Aeroneb
® 
Go 
(Aerogen, Inc., USA) vibrating mesh nebulizer. 
The PARI LC Plus nebulizer is the “gold standard” for aerosolized medication 
delivery. It is a breath-enhanced open-vent jet nebulizer that uses two valves to 
maximise aerosol delivery and minimise medication wastage. The inspiratory valve is 
opened during inspiration to allow extra air to be sucked through the nebulizer 
chamber and closed during exhalation to decrease air flow through the chamber. It is 
designed for children as well as adults and works with any compressor. It is a reusable 
nebulizer that is recommended for six months use and it can be cleaned in the 
dishwasher, boiled or autoclaved. 
The Sidestream® attached to Porta-Neb® compressor is fast, accurate drug delivery 
every time.  It is a constant-output open-vent jet nebulizer. The open vent on the top 
of nebulizer chamber improves aerosol output by allowing the negative pressure to 
suck extra air into the chamber. This markedly increases the air flow out of the 
nebulizer and pushes out more small droplets to be inspired. The aerosol is produced 
or released constantly during inspiration and expiration. It is a reusable nebulizer and 
can be cleaned in the dishwasher, boiled or autoclaved. 
The MicroAir
®
 NE-U22 nebulizer uses an ultrasonic transducer to generate vibration 
(180 kHz) of the drug solution and push the droplets through the static mesh which 
can then be inhaled directly by the patient. Unlike jet and ultrasonic nebulizers, the 
aerosol is not recycled in the mesh nebuliser. The mesh cannot be disinfected by an 
autoclave process and should be submerged in a 0.1% benzalkonium solution. 
The Aeroneb
®
 Go nebulizer has a novel design and generates aerosol using the 
OnQ
TM
 electronic micropump. It consists of a domed aperture plate with precision-
formed holes (1000 holes) and a vibrational element which vibrates at 100 kHz. This 
creates a micro-pumping action producing a fine particle, low velocity aerosol using 
7 
 
no propellants or compressors. It cannot be disinfected by an autoclave process and 
there are no specific recommendations for disinfecting. 
The nebulizer fill volumes were 5 ml and 2.5ml for jet and new nebulizers, 
respectively. Twelve volunteers (3 females) received inhaled tobramycin (TOBI
®
; 
Chiron Corporation, Emeryville, USA):
 
300mg/5ml dose from Pari LC Plus
®
 and 
Sidestream
®
, and 150mg/5ml from NE-U22-E Omron
®
 and Aeroneb
®
 Go, on separate 
randomised study days, each separated by seven days apart.  
All subjects were trained on how to use normal tidal breathing through their mouth 
during nebulization, and how to use the nebulizer device according to the 
manufacturer’s patient information sheet. A low resistance electrostatic filter pad, 
which represents the exhalation filter, was connected to the nebuliser system by T-
piece to captured waste aerosol released during expiration, a schematic diagram as 
shown in Figure1. 
 
 
Figure 1   Schematic diagram of the general nebulization method was used for 
pharmacokinetic study. 
 
All subjects voided their bladder 15 min pre-dosing. They swallowed 10g activated 
charcoal (Cabomix
®
, Penn Pharmaceuticals, Tredegar, Gwent, UK) in 50ml of water 
immediately before, and another 10g charcoal in 50ml of water after each nebulized 
dose. Time zero was started on the first inhalation, and nebulization of each dose was 
continued until dryness of inhaled solution, and the time was recorded. After 
nebulization, the residual amount of tobramycin which remained in chamber, 
mouthpiece and on exhalation filter was determined by HPLC.   
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Urine samples were collected at 0.5, 1, 2, 3 4, 6, 9, 12 and 24 hr post-inhalation of 
each study dose. Urine was pooled during each collection time; aliquots were 
transferred to plastic bottles, and stored at 4
o
 C. All samples were frozen at -20
o
 C 
prior to analysis by HPLC. 
The amount of tobramycin excreted in the urine during each collection period was 
determined analytically by HPLC assay, and then the cumulative amount excreted 
over the 24hr (Ae24) post-nebulised dose was calculated.  By using one-way ANOVA, 
all tested nebulizer systems were compared to Pari LC
 
Plus
®
 which was the reference 
nebuliser system. Comparisons between the tested nebulizers and the reference were 
made for the Ae24, and for the amount of tobramycin excreted in the first 30 min.  
From the profiles of urinary tobramycin excretion against the midpoint of the 
collection period, the tmax was obtained.  Comparison of tmax between the reference 
and tested nebulizers was also made. For each nebulizer system, comparisons of the 
relative bioavailability of tobramycin to the lung were made to the total dose available 
for inhalation, fine particle dose, and the mass median aerodynamic diameter 
(MMAD). 
The in-vitro aerodynamic particle size characteristics of TOBI
®
 emitted from each 
nebulizer systems (n=6) was determined according to the CEN (Committee European 
de Normalization) method [52]. 
 
2.6   Tobramycin Assay 
The tobramycin concentration was determined by using validated HPLC method 
following pre-column derivatization with fluorescein isothiocyanate (FITC) [53]. The 
Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/ 2009, 
21 July 2011 [54] was used as a guide to  validated the analytical method. 
 
Results and discussion  
Twelve (3 females) healthy adult subjects completed the pharmacokinetic study. Their 
mean (SD) age, weight, and height were 32.5 (6.2) years, 76.11 (9.5) kg, and 173.58 
(3.8) cm, respectively. From their urinary excretion profiles after receiving inhaled 
tobramycin 300 mg/5ml, using Pari LC Plus
®
 and Sidestream
®
 jet nebulizers, and 150 
mg/2.5 ml, using electronic mesh nebulizers (Omron
®
 and Aeroneb
®
 Go), the mean 
(SD) amounts of tobramycin excreted in the first 30 min were 0.5 (0.2), 0.4 (0.2), 0.4 
(0.25), and 0.426 (0.12) mg, respectively. The cumulative urinary excretion profiles 
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over 24 hr are shown in Figures 2 (a) and 2 (b). The median (range) tmax values were 
3.5 (2.5 –7.5) hr for jet nebulizers, and 2.5 (1.5 – 5) hr for vibrating mesh nebulisers.  
The NE-U22-E Omron
®
 showed less drug wastage, while Aeroneb Go
®
 showed 
shortest nebulization time. The in vivo study data are summarised in Tables 2 (a - b) 
and 3 (a - b). As shown in Table 4, the tested nebulizers were compared to Pari LC 
Plus
®
, which is recommended by the manufacturer of TOBI
®
, combined with 
PariBoyN
®
 compressor, by using one-way ANOVA test.   
The mean (SD) MMAD of the drug particles from Pari LC Plus
®
, Sidestream
®
, NE-
U22-E Omron
®
 and Aeroneb
® 
Go nebulizer systems was 2 (0.2), 2 (0.2), 1.2 (0.03) 
and 2.0  (0.1) µm, and the corresponding fine particle doses (FPD) were 2.2 (0.2), 1.5 
(0.2), 3.4 (0.3) and 2.81(0.3) mg. All nebulized aerosol droplets were polydispersed, 
with span values ranging between 2.93-5.37µm for jet nebulizers, and 1.76-2.21µm 
for vibrating mesh nebulizers. 
Nebulizer aerosol delivery is largely dependent on the nebulizer design and brand [55, 
56]. In this study, the effect of nebulizer design on improving tobramycin aerosol 
delivery has been studied by using different nebulizer delivery systems. Two different 
designs of jet nebulizers and new nebulizers based on vibrating mesh technology have 
been used, the constant output Sidestream
®
 and breath-enhanced Pari LC Plus
®
 jet 
nebulizers. As shown in Table 4, the cumulative amount of tobramycin over 24 hr 
(Ae24) and the relative lung bioavailability of tobramycin were significantly increased 
(p<0.05) in breath-enhanced Pari LC Plus
®
 when compared to the constant output 
Sidestream
®
 jet nebulizer. Furthermore, the amount of tobramycin left in chamber 
was highly significantly decreased (p<0.001) in the breath-enhanced Pari LC Plus
®
 
nebuliser.   However, the relative lung bioavailability of drug was highly significantly 
increased (p<0.05) using vibrating mesh nebulizers, which reflects their efficiency to 
nebulize inhaled tobramycin. No significant difference was found between the amount 
of tobramycin excreted in the first 30 min in all tested nebulizers and the reference. 
As shown in Figure 6, the residual volume percentage was highly significantly 
decreased in vibrating mesh nebulisers compared to jet nebulizers.  
Decreasing the nebulization time also was highly significant in Aeroneb
®
 Go 
nebulizer compared to all tested nebulizers. 
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In conclusion, , the lung bioavailability of tobramycin was poor following 
nebulization with jet nebulizers, while it was greater using electronic mesh nebulizer. 
The urinary pharmacokinetic method can be successfully employed in the 
determination of the relative lung bioavailability of tobramycin. The amount of 
tobramycin excreted in the urine in the first 30 minutes post-inhalation indicates the 
relative deposition of inhaled tobramycin in the lungs. The cumulative amounts of 
tobramycin excreted in the urine over the 24 hrs reflect the lung bioavailability. This 
index has been used to compare the performance of different nebuliser systems.  
When the in-vitro and in-vivo study data are combined, the new technology nebulizers 
which depend on vibrating mesh are more efficient to nebulize TOBI
®
 solution than 
jet nebulizers. Furthermore, the least drug wastage which was observed in vibrating 
mesh nebulizers helps the CF patients to continue the routine therapy of TOBI
®
 by 
reducing medication cost and have shorter nebulisation times that should improve a 
patient
’
s quality of life and compliance. 
 
 
 
Figure 2 (a) The mean (SD) urinary excretion rate time profile for tobramycin 
obtained from 12 subjects following nebulized dosing of TOBI
®
, using the different 
nebulizer systems. 
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Figure 2 (b) The mean (SD) cumulative amounts (mg) of tobramycin excreted in the 
urine following administration of nebulized dose of TOBI
®
, using the different 
nebulizer systems
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Figure 3 Mean (SD) lung bioavailability of nebulized doses obtained by selected 
nebulizer systems. 
 
 
 
 
 
 
Figure 4 Mean (SD) residual volume percentage of nebulized doses obtained by 
selected nebulizer systems. 
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